New Zealand markets closed
  • NZX 50

    +29.57 (+0.25%)

    +0.0004 (+0.07%)

    +0.0005 (+0.09%)

    +33.90 (+0.43%)
  • ASX 200

    +32.40 (+0.43%)
  • OIL

    -0.54 (-0.69%)
  • GOLD

    +0.10 (+0.00%)

    +525.80 (+3.01%)
  • FTSE

    +23.84 (+0.31%)
  • Dow Jones

    +456.87 (+1.18%)
  • DAX

    +5.87 (+0.03%)
  • Hang Seng

    -17.09 (-0.10%)
  • NIKKEI 225

    +836.48 (+2.19%)

    +0.1430 (+0.15%)

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023

Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08.

Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a listen-only mode. Following the speakers’ commentary, there will be a question-and-answer session. I will now turn the call over to Tiffany Hamilton, Ocugen’s Head of Corporate Communications. You may begin.

Tiffany Hamilton: Thank you, operator and good morning, everyone. Joining me on today’s call and webcast is Dr. Shankar Musunuri, Ocugen’s Chairman and CEO and Co-Founder, who will provide a business update and an overview of our clinical and operational progress; Michael Breininger, our Corporate Controller is also on the call to provide a financial update for the quarter ended September 30 2023; Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research, Development and Medical, will be available to answer questions following the presentation. This morning, we issued a press release detailing associated business and operational highlights for the third quarter of 2023. We encourage listeners to review the press release, which is available on our website at

A researcher conducting a clinical trial to evaluate the efficacy of a gene therapy.
A researcher conducting a clinical trial to evaluate the efficacy of a gene therapy.

This call is being recorded and a replay with the accompanying slide presentation will be available on the Investors section of the Ocugen website for approximately 45 days. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may in some cases use terms such as predicts, believes, potential, proposed, continue, estimate, anticipate, expect, plans, intends, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements include, but are not limited to statements regarding our clinical development activities and related anticipated timelines.

Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission, SEC, including the risk factors described in the section titled, Risk Factors, and the quarterly and annual reports we file with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of the presentation. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation whether as a result of new information, future events or otherwise after the date of this presentation.

Finally, Ocugen’s quarterly report on Form 10-Q covering the third quarter of 2023 has been filed. I will now turn the call to Dr. Musunuri.

See also 10 Best Cheap Stocks To Buy For the Long Term and 12 Countries That Produce the Best Movies.

To continue reading the Q&A session, please click here.